VarCov Co’s Cytokinetics CYTK Stock Holding History

VarCov Co’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,805	Closed	-$514K	–	412
2026 Q1	$514K	Buy	7,805 +1,792	+30%	+$114K	0.19%	203
2025 Q4	$382K	Buy	+6,013	New	+$374K	0.15%	233

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VarCov Co's CYTK Position: Q2 2026 in Review

VarCov Co sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 7,805 shares — an estimated $514K sold.

VarCov Co first reported a position in CYTK in Q4 2025 and held it in 2 quarters. The position peaked at $514K in Q1 2026. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

VarCov Co reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
VarCov Co sold 7,805 Cytokinetics shares in Q2 2026, an estimated $514K.
VarCov Co first reported a position in Cytokinetics in Q4 2025 and held it in 2 quarters.
VarCov Co's Cytokinetics position peaked at $514K in Q1 2026.
479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.